Neuland Laboratories Ltd. (NEULANDLAB) AI Stock Analysis

• Market Cap: ₹206.88B
• Dividend Yield: 0.07%
• Average Volume (3M): 2.41K
• Price to Earnings (P/E): 86.1
• Beta (1Y): 0.77
• Revenue Growth: 0.34%
• EPS Growth: -14.13%
• Country: IN
• Employees: 1,643
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 75.50
• Shares Outstanding: 12,829,889
• 10 Day Avg. Volume: 1,318
• 30 Day Avg. Volume: 2,408
• PEG Ratio: -4.25
• Price to Book (P/B): 9.66
• Price to Sales (P/S): 9.98
• P/FCF Ratio: 132.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹17,225.00
• Price Target Upside: 9.15% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: ₹18,609.00 ▲(17.92% Upside)

Neuland Laboratories shows strong financial performance with significant revenue growth and a robust balance sheet. However, the high P/E ratio suggests overvaluation, and technical indicators point to potential overbought conditions. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Business Model Strength

Neuland Laboratories' dual business model allows it to cater to diverse client needs, enhancing revenue stability and market adaptability.

Balance Sheet Health

A strong balance sheet with controlled leverage indicates financial stability, supporting long-term growth and operational resilience.

Cash Generation Ability

Consistent operating cash flow ensures the company can meet its operational needs and invest in growth opportunities, despite some variability.

Negative Factors

Revenue Growth Trends

A significant decline in revenue growth could impact the company's ability to expand and maintain its market position in the long term.

Earnings Volatility

Volatility in net profit margins suggests challenges in maintaining consistent profitability, which could affect investor confidence and strategic planning.

Rising Debt Levels

Increasing debt levels can strain financial resources and limit flexibility, posing risks to long-term financial health if not managed carefully.

Neuland Laboratories Ltd. Business Overview & Revenue Model

Company Description

Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.

How the Company Makes Money

Neuland Laboratories generates revenue primarily through the sale of Active Pharmaceutical Ingredients (APIs) and intermediates to pharmaceutical companies worldwide. The company operates on a business model that includes both contract manufacturing and proprietary product development, allowing it to cater to diverse client needs. Key revenue streams include bulk sales of APIs, custom synthesis projects, and partnerships with multinational pharmaceutical firms. Additionally, the company benefits from strategic alliances that enhance its market reach and product offerings, contributing significantly to its earnings. Factors such as regulatory compliance, production capacity, and technological advancements also play a crucial role in driving revenue growth.

Neuland Laboratories Ltd. Financial Statement Overview

Summary

Neuland Laboratories presents a strong financial position with substantial revenue growth and improving margins. The balance sheet is robust with a strong equity position, though there is a notable increase in debt. Cash flow management is sound but shows some variability. Overall, the company is well-positioned for future growth, though attention to debt levels and cash flow stability is advisable.

Income Statement

Neuland Laboratories has demonstrated significant revenue growth over the past five years, with a notable jump from 2020 to 2024. Margins have generally improved, particularly the gross profit margin, indicating efficient cost management. However, net profit margins have seen mixed results, indicating potential volatility in net earnings. Overall, the income statement reflects a strong growth trajectory with some fluctuations in profitability.

Balance Sheet

The company's balance sheet is robust, with a strong equity position and a healthy debt-to-equity ratio, indicating prudent financial leverage. The equity ratio is high, which showcases stability and a solid asset base. However, there is a notable increase in total debt over recent years, which could pose a risk if not managed carefully. Overall, the balance sheet suggests financial stability with controlled leverage.

Cash Flow

Neuland Laboratories has shown consistent operating cash flow, supporting its operational needs. Free cash flow has improved significantly since 2020, although there was a decrease in 2025. The operating cash flow to net income ratio suggests efficient cash generation relative to net income. However, fluctuations in free cash flow growth indicate potential variability in cash generation capacity. Overall, cash flow management appears sound but with some variability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	13.30B	14.77B	15.59B	11.61B	9.23B	9.24B
Gross Profit	6.40B	7.26B	8.25B	5.47B	3.70B	3.63B
EBITDA	3.14B	4.20B	4.75B	2.79B	1.40B	1.63B
Net Income	1.76B	2.60B	3.00B	1.64B	638.22M	806.31M
Balance Sheet
Total Assets	0.00	21.80B	18.33B	15.80B	13.83B	13.25B
Cash, Cash Equivalents and Short-Term Investments	2.40B	3.67B	1.03B	454.16M	84.68M	105.51M
Total Debt	0.00	1.57B	953.90M	1.28B	2.41B	1.82B
Total Liabilities	-15.25B	6.55B	5.50B	5.86B	5.43B	5.38B
Stockholders Equity	15.25B	15.25B	12.83B	9.94B	8.41B	7.86B
Cash Flow
Free Cash Flow	0.00	1.11B	1.18B	1.71B	-372.97M	839.65M
Operating Cash Flow	0.00	3.17B	2.61B	2.37B	603.89M	1.89B
Investing Cash Flow	0.00	-2.98B	-1.50B	-614.99M	-955.16M	-844.24M
Financing Cash Flow	0.00	249.61M	-692.82M	-1.36B	377.21M	-1.14B

Neuland Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 15781.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NEULANDLAB, the sentiment is Neutral. The current price of 15781.2 is below the 20-day moving average (MA) of 16585.16, below the 50-day MA of 16563.90, and above the 200-day MA of 13712.14, indicating a neutral trend. The MACD of -112.54 indicates Positive momentum. The RSI at 45.19 is Neutral, neither overbought nor oversold. The STOCH value of 21.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:NEULANDLAB.

Neuland Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATCOPHARM	76 Outperform	₹165.15B	10.73	―	0.57%	-3.79%	-20.88%
GRANULES	73 Outperform	₹139.17B	27.13	―	0.26%	8.14%	5.18%
MARKSANS	70 Neutral	₹84.83B	24.12	―	0.43%	14.80%	1.35%
CAPLIPOINT	69 Neutral	₹147.63B	25.07	―	0.31%	11.41%	19.22%
NEULANDLAB	67 Neutral	₹206.88B	86.15	―	0.07%	0.34%	-14.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Neuland Laboratories Ltd. Corporate Events

Neuland Laboratories Schedules Q2 FY26 Earnings Call

Neuland Laboratories Limited has scheduled an earnings call on November 7, 2025, to discuss its financial results for the second quarter and half-year ending September 30, 2025. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.

Neuland Laboratories Opens Special Window for Share Transfer Requests

Neuland Laboratories Limited has announced a special window for the re-lodgement of transfer requests for physical shares. This move, as per the Securities and Exchange Board of India’s regulations, aims to facilitate the transfer process for stakeholders, potentially impacting the company’s shareholding structure and providing clarity to investors.

Neuland Laboratories Announces Executive Restructuring via Postal Ballot

Neuland Laboratories Ltd. has announced a postal ballot notice seeking shareholder approval for the re-designation of key executive positions within the company. Mr. Davuluri Sucheth Rao is proposed to be re-designated as Executive Vice Chairman, and Mr. Davuluri Saharsh Rao as Chief Executive Officer & Managing Director. This move is part of the company’s strategic management restructuring, potentially impacting its operational leadership and signaling a shift in its corporate governance structure. The voting process will be conducted through remote e-voting, facilitated by NSDL, ensuring all members can participate electronically.

Neuland Laboratories Issues Corrigendum to Postal Ballot Notice

Neuland Laboratories Limited has announced a newspaper advertisement regarding a corrigendum to the Postal Ballot Notice, as published in Financial Express and Nava Telangana on September 18, 2025. This announcement is part of the company’s compliance with the Securities and Exchange Board of India’s regulations, ensuring stakeholders are informed of any amendments to official notices.

Neuland Laboratories Opens Special Window for Physical Share Transfers

Neuland Laboratories Ltd. has announced a special window for the re-lodgement of transfer requests for physical shares. This initiative, communicated through newspaper advertisements, aims to facilitate shareholders in updating their records in compliance with the Securities and Exchange Board of India’s regulations, potentially impacting shareholder engagement and administrative processes.